(Q42443827)

English

Beneficial influence of carvedilol on urologic indices in patients with hypertension and benign prostatic hyperplasia: results of a randomized, crossover study.

scientific article published on September 2013

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23987161%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Beneficial influence of carvedilol on urologic indices in patients with hypertension and benign prostatic hyperplasia: results of a randomized, crossover study (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23987161%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

prostatic hypertrophy

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23987161%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Bartosz Symonides

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23987161%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Zbigniew Gaciong

9

object named as

Zbigniew Gaciong

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23987161%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

author name string

Jacek Lewandowski

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23987161%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Jerzy Korecki

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23987161%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Krzysztof Rogowski

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23987161%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Jacek Judycki

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23987161%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Artur Sieczych

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23987161%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Olga Możeńska

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23987161%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

language of work or name

0 references

publication date

1 September 2013

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23987161%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23987161%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

82

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23987161%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23987161%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

660-665

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23987161%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

High prevalence of benign prostatic hypertrophy in the community

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.087

7 January 2021

1993 guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. Guidelines Sub-Committee

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.087

7 January 2021

The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure<SUBTITLE>The JNC 7 Report</SUBTITLE>

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.087

7 January 2021

2007 Guidelines for the Management of Arterial Hypertension

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.087

7 January 2021

The pharmacology of carvedilol

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.087

7 January 2021

Clinical pharmacology of alpha1A selective and nonselective alpha1-blockers

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.087

7 January 2021

Adrenoceptor subclassification: an approach to improved cardiovascular therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.087

7 January 2021

Doxazosin in benign prostatic hyperplasia: effects on blood pressure and urinary flow in normotensive and hypertensive men

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.087

7 January 2021

Carvedilol for the treatment of benign prostatic hypertrophy in patients with heart failure?

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.087

7 January 2021

Efficacy and safety of the alpha-1 blocker doxazosin in the treatment of benign prostatic hyperplasia. Analysis of 5 studies. Doxazosin Study Groups

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.087

7 January 2021

Long-term efficacy and safety of terazosin in patients with benign prostatic hyperplasia. Terazosin Research Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.087

7 January 2021

Tamsulosin and chlormadinone for the treatment of benign prostatic hyperplasia. The Kobe University YM617 Study Group

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.087

7 January 2021

Influence of hypertension on lower urinary tract symptoms in benign prostatic hyperplasia.

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLOGY.2013.03.087

7 January 2021

Identifiers

10.1016/J.UROLOGY.2013.03.087

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23987161%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:23987161%20AND%20SRC:MED&resulttype=core&format=json

8 March 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42443827&oldid=1572322338"